Follow Binaytara on FacebookFollow Binaytara on XFollow Binaytara on LinkedinFollow Binaytara on BlueskyFollow Binaytara on Instagram
Binaytara logo
  • About Us
  • CME Conferences
  • Funding Opportunities
  • Projects
  • Get Involved
  • News
Tuesday, August 11, 2026
The Cancer News

AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER

All Articles
Cancer Education
  • Resources for Cancer Patients
Perspectives
Clinical Breakthroughs & Research
Health Equity
About Us
  • Contributors
  • Ethics and Disclosure Policy
  • Editorial Standards & Corrections Policy
Article Submission
The Cancer News>Cancer Education>New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

Browse by Topics

Cancer EducationPerspectivesHealth EquityHealth PolicyResources for Cancer PatientsResearch
More from Cancer Education
Lymphoma and CLL at ASCO 2026: New Frontline and Relapsed-Setting Data

Lymphoma and CLL at ASCO 2026: New Frontline and Relapsed-Setting Data

August 5, 2026

Managing Bispecific T-Cell Engager Toxicity: CRS and ICANs in Practice

Managing Bispecific T-Cell Engager Toxicity: CRS and ICANs in Practice

August 4, 2026

World Lung Cancer Day 2026: What Lung Cancer Doctors Want You to Know

World Lung Cancer Day 2026: What Lung Cancer Doctors Want You to Know

August 1, 2026

Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Early Intervention in Smoldering Disease

Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Early Intervention in Smoldering Disease

July 31, 2026

Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case

Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case

July 31, 2026

Pancreatic Cancer: A RAS Inhibitor Nearly Doubles Survival, and a KRAS Vaccine Shows Real Promise

Pancreatic Cancer: A RAS Inhibitor Nearly Doubles Survival, and a KRAS Vaccine Shows Real Promise

Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance

Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance

Share Article

Get the Quick Bites delivered to your inbox daily

Binaytara logo

19-years of advocating, educating and innovating to improve Cancer Care.

Useful Links

  • News and Stories
  • OncoBlast
  • Careers
  • Donate

US Address

  • Binaytara
  • 3380 146th Pl SE, Suite 340
  • Bellevue, WA 98007 USA

Nepal Address

  • Binaytara Country Office
  • Kadam Chowk
  • Janakpur, NEPAL
  • _______
  • Binaytara Cancer Center
  • Janakpur, NEPAL

Legal

  • Privacy Policy

Binaytara is a 501(c)(3) not-for-profit organization. Our EIN number. is 26-1603676. © 2026, Binaytara. All rights reserved

Follow Binaytara on FacebookFollow Binaytara on BlueskyFollow Binaytara on LinkedinFollow Binaytara on YoutubeFollow Binaytara on TwitterFollow Binaytara on Instagram